Loading…
Employees: 1,236
Size Zhejiang Anglikang Pharmaceutical (002940.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $801M, the 2758th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥26.76 on 6 Nov 2026.
Performance Over six months the shares fell 19.1%, against -7.8% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 5.9% over the last twelve months (peer median +3.5%); the operating margin is 10.4% (peer median 7.3%).
Valuation It trades at 4.2× enterprise value to sales against a peer median of 2.4× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.7 points below its cost of capital (6.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.33B | CN¥1.42B | CN¥1.52B | CN¥1.61B | CN¥1.55B |
| Revenue growth | — | -7% | -5% | +4% | — |
| Gross profit | CN¥500M | CN¥527M | CN¥574M | CN¥680M | CN¥864M |
| EBITDA | CN¥216M | CN¥228M | CN¥204M | CN¥242M | CN¥196M |
| Net income | CN¥114M | CN¥125M | CN¥80.3M | CN¥138M | CN¥127M |
| Free cash flow | CN¥241M | CN¥196M | CN¥162M | CN¥155M | CN¥117M |
| Capital expenditure | CN¥57.8M | CN¥49.9M | CN¥94.5M | CN¥125M | CN¥68.8M |
| Total debt | CN¥812M | CN¥733M | CN¥805M | CN¥796M | CN¥570M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002940.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.0% | -3.6% | 2nd highest of 20 |
| 6-month return | -19.1% | -7.8% | 6th lowest of 20 |
| Distance from 52-week high | -45.3% | -30.4% | 4th lowest of 20 |
| Revenue growth (TTM) | -5.9% | +3.5% | 5th lowest of 19 |
| Operating margin | 10.4% | 7.3% | 9th highest of 19 |
| EV / Sales | 4.2× | 2.4× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 18.2% | -1.1% | most demanding of 12 |
| Growth delivered (Del g) | +2.1% | +2.6% | 6th lowest of 12 |
| Hurdle (Req g minus delivered) | +16.2 pp | -2.2 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | -1.7 pp | +2.1 pp | 7th lowest of 17 |
| EV / EBITDA | 25.8× | 11.2× | most expensive of 8 |
| Net debt / EBITDA | -0.1× | -0.5× | 3rd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | 32.3× | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | 0.3× | n/a | n/a |